Related Experiment Video
Updated: Jul 2, 2026
08:04
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
Tissue necrosis after chemotherapy in osteosarcoma as the important prognostic factor
Sam H Sami1, Ali H Rafati, Parsa Hodjat
1Department of Orthopedic Surgery, Iran University of Medical Sciences, Iran.
Saudi Medical Journal
|August 12, 2008
Summary
Histological response to preoperative chemotherapy significantly predicts outcomes in osteosarcoma patients. Higher tumor necrosis indicates better event-free survival, guiding treatment intensity for high-risk individuals.
Area of Science:
- Oncology
- Pathology
Background:
- Osteosarcoma is a primary bone malignancy.
- Neoadjuvant chemotherapy is a standard treatment modality.
Purpose of the Study:
- To evaluate the histological response to neoadjuvant chemotherapy in osteosarcoma.
- To correlate histological response with oncological outcomes.
Main Methods:
- Eighty osteosarcoma patients received neoadjuvant and adjuvant chemotherapy.
- Tumor specimens were graded based on percentage of tumor necrosis (Grade 1: ≤50%, Grade 2: >50%-<90%, Grade 3: >90%).
Main Results:
- Histological response was a significant predictor of event-free survival (p=0.016).
- Event-free survival rates at 12, 24, and 40 months were 86%, 50%, and 21%, respectively.
- Median survival for event-free patients was 1096 days.
Conclusions:
- Histological response to neoadjuvant chemotherapy is a crucial prognostic indicator in osteosarcoma.
- This assessment can identify patients requiring more intensive or novel therapeutic strategies.
- Identifying high-risk patients aids in personalized treatment planning.
